PRA Health Sciences (NASDAQ:PRAH) Receives Daily Coverage Optimism Rating of 0.31

News coverage about PRA Health Sciences (NASDAQ:PRAH) has been trending positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. PRA Health Sciences earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

PRA Health Sciences (NASDAQ PRAH) traded down 0.42% during midday trading on Tuesday, hitting $75.21. 20,131 shares of the stock traded hands. The company’s 50 day moving average price is $72.62 and its 200 day moving average price is $63.15. The firm has a market cap of $4.70 billion, a PE ratio of 44.93 and a beta of 0.48. PRA Health Sciences has a 12 month low of $41.01 and a 12 month high of $79.98.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Tuesday, April 25th. The medical research company reported $0.60 EPS for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.02. The company had revenue of $427.08 million for the quarter, compared to the consensus estimate of $426.81 million. PRA Health Sciences had a return on equity of 21.87% and a net margin of 5.85%. PRA Health Sciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.55 earnings per share. Equities research analysts predict that PRA Health Sciences will post $3.15 earnings per share for the current fiscal year.

Several brokerages have commented on PRAH. Citigroup Inc. restated a “buy” rating and issued a $90.00 price objective (up from $73.00) on shares of PRA Health Sciences in a report on Wednesday, June 28th. Bank of America Corporation began coverage on shares of PRA Health Sciences in a research report on Monday, June 26th. They set a “buy” rating and a $89.00 price objective on the stock. Credit Suisse Group reissued an “outperform” rating and set a $76.00 price objective (up from $69.00) on shares of PRA Health Sciences in a research report on Tuesday, June 6th. Finally, Jefferies Group LLC set a $73.00 price target on shares of PRA Health Sciences and gave the company a “buy” rating in a report on Thursday, June 1st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. PRA Health Sciences has a consensus rating of “Buy” and an average price target of $73.00.

COPYRIGHT VIOLATION WARNING: This story was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://sportsperspectives.com/2017/07/18/pra-health-sciences-prah-earns-media-sentiment-rating-of-0-31-updated-updated.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Insider Buying and Selling by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply